Abstract
Sequence alterations of the mitochondrial DNA (mtDNA) have been identified in many tumor types. Their nature is not entirely clear. Somatic mutation or shifts of heteroplasmic mtDNA variants may play a role. These sequence alterations exhibit a sufficient frequency in all tumor types investigated thus far to justify their use as a tumor marker. This statement is supported by the high copy number of mtDNA, which facilitates the detection of aberrant tumor-derived DNA in bodily fluids. This will be of special interest in tumors, which release a relatively high number of cells into bodily fluids, which are easily accessible, most strikingly in urinary bladder carcinoma. Due to the wide distribution of the observed base substitutions, deletions or insertions within the mitochondrial genome, high efforts for whole mtDNA sequencing (16.5 kb) from bodily fluids would be required, if the method would be intended for initial tumor screening. However, the usage of mtDNA for sensitive surveillance of known tumor diseases is a meaningful option, which may allow an improved noninvasive follow-up for the urinary bladder carcinoma, as compared to the currently existing cytological or molecular methods. Following a short general introduction into mtDNA, this review demonstrates that the scenario of a sensitive cancer follow-up by mtDNA-analysis deserves more attention. It would be most important to investigate precisely in the most relevant tumor types, if sequencing approaches in combination with simple PCR-assays for deletions/insertions in homopolymeric tracts has sufficient sensitivity to find most tumor-derived mtDNAs in bodily fluids.
Keywords: Bladder cancer, Cancer risk, Cancer surveillance, Heteroplasmy, MitoChip, mtDNA, NGS.
Current Genomics
Title:MtDNA As a Cancer Marker: A Finally Closed Chapter?
Volume: 18 Issue: 3
Author(s): Elmar Kirches*
Affiliation:
- Otto-von-Guericke University, Magdeburg,Germany
Keywords: Bladder cancer, Cancer risk, Cancer surveillance, Heteroplasmy, MitoChip, mtDNA, NGS.
Abstract: Sequence alterations of the mitochondrial DNA (mtDNA) have been identified in many tumor types. Their nature is not entirely clear. Somatic mutation or shifts of heteroplasmic mtDNA variants may play a role. These sequence alterations exhibit a sufficient frequency in all tumor types investigated thus far to justify their use as a tumor marker. This statement is supported by the high copy number of mtDNA, which facilitates the detection of aberrant tumor-derived DNA in bodily fluids. This will be of special interest in tumors, which release a relatively high number of cells into bodily fluids, which are easily accessible, most strikingly in urinary bladder carcinoma. Due to the wide distribution of the observed base substitutions, deletions or insertions within the mitochondrial genome, high efforts for whole mtDNA sequencing (16.5 kb) from bodily fluids would be required, if the method would be intended for initial tumor screening. However, the usage of mtDNA for sensitive surveillance of known tumor diseases is a meaningful option, which may allow an improved noninvasive follow-up for the urinary bladder carcinoma, as compared to the currently existing cytological or molecular methods. Following a short general introduction into mtDNA, this review demonstrates that the scenario of a sensitive cancer follow-up by mtDNA-analysis deserves more attention. It would be most important to investigate precisely in the most relevant tumor types, if sequencing approaches in combination with simple PCR-assays for deletions/insertions in homopolymeric tracts has sufficient sensitivity to find most tumor-derived mtDNAs in bodily fluids.
Export Options
About this article
Cite this article as:
Kirches Elmar*, MtDNA As a Cancer Marker: A Finally Closed Chapter?, Current Genomics 2017; 18 (3) . https://dx.doi.org/10.2174/1389202918666170105093635
DOI https://dx.doi.org/10.2174/1389202918666170105093635 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Relationships of Beta2- and Beta3--Adrenoceptor Polymorphisms with Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Current Drug Targets Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications
Current Diabetes Reviews microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents
Current Medicinal Chemistry Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued) Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Comprehensive Profile of <i>Madhuca Longifolia</i> in Pharma and Food Industry
Current Nutraceuticals Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy